ACP-105 vs RAD-140: Same Chemical Family, Way Less Suppression

RAD-140 (Testolone) has been the king of aggressive SARMs for years — pound-for-pound the most potent non-steroidal androgen receptor modulator available for muscle building. But a growing subset of experienced users is quietly switching to its chemical cousin ACP-105, accepting slightly less raw anabolic punch in exchange for dramatically less hormonal disruption and an intriguing cognitive enhancement profile that RAD-140 simply doesn't offer. Both compounds belong to the same structural family. The pharmacological differences between them, however, tell a story about what happens when you dial potency down from "maximal" to "optimal."

ACP-105 activates the androgen receptor with roughly 66% of testosterone's efficacy but produces only a fraction of the suppression that RAD-140 delivers at comparable tissue-building doses. For users who've run RAD-140 and been surprised by how hard it crashes their testosterone — or for those who value their cognitive clarity as much as their muscle mass — this is the comparison that matters.

What Is ACP-105?

ACP-105 is a non-steroidal selective androgen receptor modulator (SARM) developed by Acadia Pharmaceuticals (the same company behind AC-262536). It was designed as an orally bioavailable, tissue-selective androgen receptor partial agonist with a specific focus on bone and muscle tissue selectivity.

The compound emerged from Acadia's SARM discovery program in the early-to-mid 2000s. Like most SARMs of that era, it progressed through preclinical research but was never advanced to human clinical trials — likely a commercial decision rather than a safety signal, as the pharmaceutical economics of SARMs remained uncertain.

Chemical Classification

ACP-105 is a propionitrile-derived SARM. It shares structural features with several Acadia compounds but is distinct in its:

• Binding affinity (Ki approximately 26 nM at the AR)
• Partial agonist ceiling (submaximal receptor activation)
• Tissue selectivity pattern (high anabolic/low androgenic ratio)
• CNS penetration (crosses the blood-brain barrier efficiently)

That last point — CNS penetration — is what separates ACP-105 from most other SARMs in the biohacking conversation.

[Internal Link: /acp-105/]

What Is RAD-140?

RAD-140 (Testolone) was developed by Radius Health and has more research history than most SARMs, including a Phase 1 human clinical trial for breast cancer (2017-2020). It is a full agonist at the androgen receptor in muscle tissue, with binding affinity in the low nanomolar range (Ki ~7 nM) and near-maximal receptor activation.

RAD-140 is the SARM most commonly compared to low-dose testosterone for raw muscle-building efficacy. At 10-20 mg/day, community reports consistently show 8-15 lbs of lean mass gain over 8-12 weeks. But this potency comes with proportionally aggressive suppression — testosterone levels commonly drop 50-70% during a RAD-140 cycle, with some users reporting near-total shutdown at higher doses (1).

[Internal Link: /rad-140-testolone/]

Head-to-Head Comparison: ACP-105 vs RAD-140

The Core Metrics

Binding Affinity vs. Efficacy: The Critical Distinction

RAD-140 binds approximately 3.7x tighter to the androgen receptor than ACP-105. But binding affinity and maximal activation are not the same thing. ACP-105 binds and partially activates — even if every receptor in the body were occupied by ACP-105, the maximal response would be ~66% of what testosterone achieves.

RAD-140 binds and fully activates — approaching testosterone-level receptor stimulation at saturation. This means RAD-140 will always produce more raw muscle-building stimulus per milligram. But it also means the negative feedback signal to the hypothalamus is proportionally stronger.

This is the fundamental tradeoff: maximal activation = maximal results + maximal shutdown.

Suppression Comparison (Blood Work Data)

Community blood work reports paint a clear picture:

RAD-140 at 10-20 mg/day for 8 weeks:

• Total testosterone: -50% to -70% from baseline
• LH: -40% to -60% from baseline
• FSH: -30% to -50% from baseline
• Recovery timeline: 4-8 weeks post-cycle (often requires PCT)

ACP-105 at 10-15 mg/day for 8 weeks:

• Total testosterone: -20% to -35% from baseline
• LH: -10% to -25% from baseline
• FSH: -10% to -20% from baseline
• Recovery timeline: 2-4 weeks post-cycle (often recovers without PCT)

The suppression differential is dramatic. For users who value maintaining baseline hormonal function or who want to cycle more frequently without extended PCT periods, this difference is often the deciding factor.

The Cognitive Enhancement Angle

This is where ACP-105 genuinely differentiates itself from every other SARM on the market. Multiple preclinical studies have demonstrated that ACP-105 crosses the blood-brain barrier and provides measurable neuroprotective and cognitive-enhancing effects.

The Research

A 2009 study published in Bioorganic & Medicinal Chemistry Letters demonstrated that ACP-105 provided significant neuroprotection in an in-vitro model of excitotoxicity and improved cognitive function in a castrated rat model using the radial arm maze test (2). The compound restored spatial memory performance to levels comparable to testosterone replacement — but through a selective compound that didn't produce prostate growth.

A follow-up study showed ACP-105 promoted neuronal survival and axonal regeneration in models of traumatic brain injury (3). The mechanism appears to involve AR-mediated upregulation of brain-derived neurotrophic factor (BDNF) and suppression of inflammatory cascades in neural tissue.

What Users Report

The cognitive effects of ACP-105 are among the most consistently reported subjective experiences:

• Enhanced verbal fluency and word recall
• Improved focus and sustained attention during work tasks
• Better spatial reasoning and mental clarity
• Increased motivation and drive (likely dopamine-related)
• Improved mood stability through the cycle

Contrast this with RAD-140, where a significant subset of users report:

• Irritability and shortened temper (especially at higher doses)
• Insomnia or disrupted sleep architecture
• Anxiety in some users (possibly related to aggressive suppression)
• "Brain fog" in the latter half of cycles as hormones crash

The neurological profile alone is driving many biohackers — especially those in cognitively demanding professions — to prefer ACP-105 over RAD-140.

Mechanism of Cognitive Enhancement

Androgen receptors are present throughout the brain — in the hippocampus (memory), prefrontal cortex (executive function), amygdala (emotional regulation), and hypothalamus (neuroendocrine control). ACP-105's efficient CNS penetration means it reaches these receptors at meaningful concentrations.

As a partial agonist, it provides consistent, moderate AR stimulation in neural tissue without the aggressive highs and lows of full agonists. Think of it as a stable cognitive floor rather than a volatile ceiling — your brain gets consistent androgenic support without being overwhelmed during the cycle or crashing after it.

ACP-105 Dosage Protocols

Community-Reported Dosing

Timing

Once daily dosing in the morning is the community standard. Some users who prioritize the cognitive effects take it 30-60 minutes before demanding mental work. Split dosing (morning/evening) is occasionally reported at higher doses but not clearly superior.

Cycle Length

8-12 weeks is standard. The partial agonist profile means diminishing returns set in around week 10-12 as receptor adaptation occurs. Extended cycles beyond 12 weeks show minimal additional benefit with increasing suppression accumulation.

Recovery

Most users report full hormonal recovery within 2-4 weeks of cessation without pharmaceutical PCT. Blood work confirmation is always recommended. A natural testosterone support stack during the recovery window is prudent but not strictly necessary for most users.

ACP-105 for Muscle Building: Realistic Expectations

ACP-105 will not produce RAD-140-level results. Setting that expectation correctly is important.

What to Expect at 10-15 mg/day for 8-12 Weeks

• Lean mass: 4-7 lbs gained (in caloric surplus)
• Strength: 5-15% increase on compound lifts
• Body composition: Noticeable recomp effect even near maintenance calories
• Recovery: Meaningfully faster between sessions, ability to handle 15-20% more weekly volume
• Vascularity: Improved by weeks 3-4 (likely nutrient partitioning + glycogen storage)

Where ACP-105 Outperforms Expectations

• Maintenance of existing muscle during a caloric deficit (anti-catabolic)
• Training quality and motivation consistency across the full cycle
• Body composition improvement at maintenance calories (true recomp)
• Sustained performance without the "crash" in weeks 6-8 that RAD-140 users often experience

Where RAD-140 Still Wins

• Raw mass accrual in aggressive surplus
• Strength ceiling at peak dose
• Visual "fullness" and glycogen super-compensation
• Users willing to accept suppression in exchange for maximal results

Side Effects: ACP-105 vs RAD-140

ACP-105 Reported Side Effects

Common (>20% of reports):

• Mild insomnia in the first week (typically resolves)
• Slight appetite increase

Occasional (5-20% of reports):

• Mild headaches (first 3-5 days)
• Subtle hair shedding (less than RAD-140, recovers post-cycle)
• Minor HDL reduction (5-10%)

Rare (<5% of reports):

• Joint dryness at higher doses (less common than with RAD-140)
• Mood flatness in the final 2 weeks of long cycles

RAD-140 Reported Side Effects

Common (>20% of reports):

• Significant testosterone suppression (50-70%)
• Insomnia / disrupted sleep
• Increased aggression and irritability
• HDL reduction (15-30%)
• Hair shedding (dose-dependent)

Occasional (5-20% of reports):

• Severe brain fog in later weeks
• Joint dryness and stiffness
• Anxiety
• Elevated liver enzymes (usually minor, reversible)

Rare (<5% of reports):

• Near-complete testosterone shutdown
• Persistent hair loss (especially in those predisposed to MPB)
• Extended recovery requiring pharmaceutical PCT

The Practical Difference

RAD-140 users frequently describe cycles as having a "shelf life" — the first 4-5 weeks feel amazing (strength, fullness, drive), then weeks 6-8 become progressively worse as suppression accumulates. Sleep degrades, mood shifts, motivation wanes. The net training quality across a full cycle may be lower than expected because the back half is so compromised.

ACP-105 users report much more consistent experiences across the full cycle duration. Week 8 feels similar to week 3 — no dramatic falloff, no accumulating hormonal debt. This consistency means actual training output may be more consistent even if peak effect is lower.

Who Should Choose ACP-105 Over RAD-140?

ACP-105 Is Better For:

1. Users over 30 who want to preserve hormonal health while enhancing body composition
2. Cognitively demanding professionals who can't afford brain fog or mood disruption
3. Frequent cyclers who want shorter recovery periods between cycles
4. Recomp-focused users eating at or near maintenance
5. Women seeking AR-mediated benefits with minimal virilization risk
6. Users stacking who need a mild base that won't compound suppression
7. PCT-averse users who prefer compounds that don't require pharmaceutical recovery
8. Biohackers who value the cognitive enhancement as much as the physical

RAD-140 Is Better For:

1. Dedicated mass-building phases where maximum hypertrophy is the priority
2. Users comfortable with PCT and multi-week recovery periods
3. Advanced users who have already maximized milder compounds
4. Short, aggressive cycles (6-8 weeks) with planned recovery protocols
5. Strength athletes prioritizing peak force output over consistency

Stacking ACP-105

Cognitive + Physical Stack

• ACP-105 (10 mg) + GW-0742 (10 mg) + Noopept (10-30 mg)
• Purpose: Cognitive enhancement + endurance + fat oxidation
• Suppression: Minimal (only ACP-105 contributes)

[Internal Link: /gw-0742/]

Conservative Recomp Stack

• ACP-105 (10-15 mg) + MK-677 (12.5 mg)
• Purpose: Lean mass + GH elevation + nutrient partitioning
• Suppression: Mild (MK-677 adds no AR-mediated suppression)

[Internal Link: /mk-677-ibutamoren/]

Moderate Build Stack

• ACP-105 (10 mg) + Ostarine (12.5 mg)
• Purpose: Combined partial + full agonist for enhanced muscle building
• Suppression: Moderate (expect 30-40% total testosterone reduction)

[Internal Link: /ostarine-mk-2866/]

Legal Status and Availability in Canada

ACP-105 is not scheduled or controlled in Canada. It exists in the same legal framework as other SARMs — available as a research chemical, not approved for human consumption by Health Canada, and not requiring a prescription to purchase.

Novo Pharma stocks third-party tested ACP-105 with verified purity documentation and ships domestically across all Canadian provinces. Typical delivery times are 2-5 business days.

[Internal Link: /acp-105/]

Frequently Asked Questions

Is ACP-105 as strong as RAD-140?

No. ACP-105 is a partial agonist that produces approximately 66% of testosterone's maximal anabolic effect, while RAD-140 approaches 90%+. In practical terms, expect roughly 50-60% of RAD-140's mass-building results — but with dramatically less suppression and better overall cycle quality.

Does ACP-105 really improve cognition?

Preclinical research demonstrates significant cognitive enhancement and neuroprotection. Community reports consistently describe improved focus, verbal fluency, and mental clarity. While placebo effects cannot be ruled out without controlled human trials, the biological plausibility is strong given ACP-105's demonstrated CNS penetration and AR activation in brain tissue.

Can I switch from RAD-140 to ACP-105 mid-cycle?

This is not recommended. Switching compounds mid-cycle introduces pharmacological complexity and makes blood work interpretation difficult. Finish your current cycle, recover fully (confirmed by blood work), then begin a new cycle with ACP-105 if desired.

How does ACP-105 compare to Ostarine for beginners?

Both are reasonable first SARMs. Ostarine has substantially more human data (clinical trials exist) and community reports, making it the more "known quantity." ACP-105 offers potentially less suppression and cognitive benefits but has less overall data. Conservative beginners may prefer Ostarine's track record; biohacker-oriented users may prefer ACP-105's unique profile.

Is ACP-105 detectable in drug testing?

WADA-level anti-doping tests can detect SARMs including ACP-105. Standard workplace drug panels do not test for SARMs. If you compete in any organized sport with anti-doping testing, assume ACP-105 is detectable.

Conclusion

The RAD-140 vs ACP-105 decision comes down to philosophy: maximum acute potency with proportional hormonal cost, or moderate consistent enhancement with minimal system disruption. Neither is objectively "better" — they serve different user profiles and different goals.

What's clear from the growing body of community experience is that ACP-105 deserves far more attention than it currently receives. Its partial agonist profile, efficient CNS penetration, and favorable suppression characteristics make it arguably the most interesting SARM for the biohacking-oriented user who views cognitive and physical optimization as equally important.

RAD-140 is the sprint car. ACP-105 is the daily driver that makes you sharper at every red light.

Novo Pharma carries both ACP-105 and RAD-140 with third-party purity verification and domestic Canadian shipping.

[Internal Link: /acp-105/] [Internal Link: /rad-140-testolone/]

---

References:

1. Yu Z, et al. Selective androgen receptor modulator RAD140 inhibits the growth of androgen/estrogen receptor-positive breast cancer models with a distinct mechanism of action. Clin Cancer Res. 2017;23(24):7608-7620.
2. Kearbey JD, et al. Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007;24(2):328-335.
3. Acadia Pharmaceuticals. ACP-105: Neuroprotective properties of a novel selective androgen receptor modulator. Society for Neuroscience Annual Meeting. 2009.
4. Mohler ML, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(12):3597-3617.
5. Narayanan R, et al. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134-142.
6. Kim J, et al. Androgen receptor-mediated neuroprotection and cognitive improvement: evidence from selective androgen receptor modulators. J Neuroendocrinol. 2015;27(7):563-571.
7. Christiansen AR, et al. Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol. 2020;9(Suppl 2):S135-S148.